NCT01275183已完成早期 1 期
A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Gene expression modification
研究概览
简要总结
The proposed study is a first-in-human pilot of a novel anti-cancer strategy: Metnase inhibition to potentiate DNA damaging chemotherapy. The investigators will conduct serial tumor biopsies in subjects with HNSCC at three timepoints: baseline, after cisplatin, and after cisplatin-raltegravir. The investigators will investigate immunohistochemical expression changes of γH2AX, Chk2, and Annexin V, three biomarkers of DNA damage and apoptosis. The study is designed to identify an intermediate signal of the potentiation of cisplatin chemotherapy by raltegravir in HNSCC, which will justify a future phase I/II study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of squamous cell carcinoma of the head and neck. All primary sites are eligible, including keratinizing nasopharyngeal carcinoma (WHO grade 1 or 2) and carcinoma of unknown primary.
- •Either the primary site or a metastatic locoregional tumor deposit (eg. lymph node, parotid gland, subcutaneous nodule) must be amenable to repeat, in-office biopsy by a head and neck surgeon.
- •The patient must be considered an appropriate candidate for cisplatin chemotherapy by a medical oncologist. Acceptable indications include induction chemotherapy prior to surgery or radiation for localized disease, or palliative chemotherapy for advanced disease.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Adequate bone marrow function, defined as an absolute peripheral granulocyte count of greater than 1,500 cells/mm3 and platelet count greater than 100,000/mm3 and absence of a regular red blood cell transfusion requirement.
- •Adequate hepatic function with a total bilirubin less than 2 mg/dl; SGOT and SGPT less than 1.5 times the upper limit of normal; alkaline phosphatase less than 2.5 times the upper limit of normal.
- •Creatinine clearance greater than or equal to 55 mL/min. Creatinine clearance will be estimated by the Cockraft-Gault formula, using actual body weight.
- •Women of childbearing potential must have a negative pregnancy test.
- •Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment, and for at least 3 months thereafter.
- •Age greater than
- •Able to provide written, informed consent.
排除标准
- •No known brain metastases.
- •Pregnant women or nursing mothers are not eligible for this trial.
- •During the first two weekly cycles of cisplatin and raltegravir, patients may receive no other concurrent antineoplastic therapy, including chemotherapy, biologic agents or radiotherapy. For subsequent induction or palliative chemotherapy cycles, patients may receive combination cisplatin-docetaxel-raltegravir, on a three-week schedule as specified in this protocol.
- •No severe medical problems, including unstable angina; myocardial infarction within the past 6 months; symptomatic congestive heart failure, NYHA grade II or higher; active infection requiring antibiotics.
- •History of hypersensitivity reaction to cisplatin.
- •Patient with known HIV disease.
- •Any comorbid condition which would preclude full compliance with the protocol.
- •Patient is less than 3 years free from another malignancy, except: a) if the other malignancy is non-melanomatous skin cancer or cervical carcinoma in situ or b) if the other primary malignancy is considered clinically insignificant and is requiring no active intervention.
- •Peripheral neuropathy greater than or equal to grade
- •Ongoing treatment with rifampin, phenytoin, or phenobarbital.
研究组 & 干预措施
Raltegravir and cisplatin
Experimental
干预措施: raltegravir and cisplatin (Drug)
结局指标
主要结局
Gene expression modification
时间窗: 3 weeks
Expression changes of three selected tumor biomarkers (DNA damage and apoptosis) will be measured at baseline, after cisplatin alone, and after raltegravir-cisplatin. Tumor biomarkers include pChk2, Annexin V, and metnase.
次要结局
- Metnase expression(2 to 6 months)
- Progression free survival and overall survival(2 years)
- Clinical activity(2 to 6 months)
- Clinical toxicity(2 to 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic CirrhosisHuman Immunodeficiency VirusHepatitis CNCT01289951Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal10
进行中（未招募）
2 期
Niraparib in Tumors Metastatic to the CNSMetastatic CancerCentral Nervous System CancerNCT04992013Massachusetts General Hospital20
撤回
1 期
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT05168748Novartis Pharmaceuticals
尚未招募
2 期
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersMetastatic Breast Cancer in Germline-PALB2 Mutations CarriersNCT05232006Assistance Publique - Hôpitaux de Paris12
进行中（未招募）
1 期
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancerNCT06052306Bayer232